ARS Pharmaceuticals’ EpiPen Alternative Delayed US Approval – Two Analysts Offer Differing Views – ARS Pharmaceuticals (NASDAQ:SPRY) Emily ClarkSeptember 21, 2023 On Tuesday, The FDA issued a Complete Response Letter regarding ARS Pharmaceuticals Inc’s SPRY New Drug Application (NDA) for neffy (epinephrine nasal spray) in the treatment of Read More